

THE SUBSCRIPTION PERIOD IN ORTOMA'S RIGHTS ISSUE BEGINS TODAY

Today, 31 March 2026, the subscription period begins in Ortoma AB (publ)'s ("Ortoma" or the "Company") rights issue of approximately SEK 52 million, before transaction costs, which was resolved by the Board of Directors on 3 March 2026 and subsequently approved by the extraordinary general meeting held on 24 March 2026 (the "Rights Issue"). The subscription period for the Rights Issue runs until 15 April 2026. Please note, however, that certain banks and custodians may have an earlier deadline for subscription in the Rights Issue. Shareholders should therefore check with their bank or custodian to see if they have an earlier deadline for subscription.

The Rights Issue in Brief

- The Rights Issue comprises a maximum of 7,416,746 new shares of series B and, if fully subscribed, will provide the Company with approximately SEK 52 million before transaction-related costs.
- The subscription price in the Rights Issue is SEK 7.0 per share.
- The Company's shareholders have preferential rights to subscribe for shares in the Rights Issue, whereby each existing share entitles the holder to one (1) subscription right, and five (5) subscription rights entitle the holder to subscribe for one (1) new share.
- The record date for participation in the Rights Issue was 27 March 2026. The last day of trading in the Company's shares including the right to participate in the Rights Issue was 25 March 2026.
- The subscription period in the Rights Issue will run from 31 March to 15 April 2026.
- Trading in subscription rights is expected to take place on Nasdaq First North Growth Market during the period 31 March to 10 April 2026.
- The Rights Issue is fully covered by subscription commitments and guarantee undertakings.

Full terms and conditions and instructions for the Rights Issue are set out in the information document published on 27 March 2026 (the "**Information Document**"). The Information Document is available on the Company's website, www.ortoma.com.

Timetable for the Rights Issue

Trading in subscription rights	31 March – 10 April 2026
Subscription period	31 March – 15 April 2026
Trading in paid subscribed shares (BTA)	31 March – 22 April 2026
Publication of outcome	On or about 17 April 2026
Trading in new shares[1]	28 April 2026

Advisors

DNB Carnegie Investment Bank AB acts as Sole Global Coordinator and Sole Bookrunner in connection with the Rights Issue. Norma Advokater KB is legal adviser to the Company.

Important information

Publication, release, or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where the press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in Ortoma AB (publ) in any jurisdiction, either from Ortoma AB (publ) or from anyone else. This press release is not a prospectus according to the definition in the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. A disclosure document prepared in accordance with Article 1.4 (db) and Annex IX of the Prospectus Regulation regarding the Rights Issue described in this press release has been prepared and published by the Company prior to the commencing of the subscription period.

This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 (“**Securities Act**”), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to United States, Australia, Hongkong, Israel, Canada, Japan, South Africa, New Zealand, Switzerland, Singapore, Russia, Belarus, South Korea or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.

Please note that an investment in the Company is subject to regulation under the Foreign Direct Investment Act (2023:560), which requires investors, under certain conditions, to notify and obtain approval from the Swedish Inspectorate for Strategic Products. Investors should make their own assessment of whether a notification obligation exists before making any investment decision.

[1] Note that depending on different routines at different banks and custodians the trading may begin before or after this date

For further information, please contact:

Yvonne Mårtensson, Chairman of the Board

Fredrik Strömberg, CEO

E-post: info@ortoma.com

About Us

Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The purpose of the company's surgical system, Ortoma Treatment Solution™ (OTS) is to enable surgeons to accurately measure and plan 3D surgery for the placement of joint implants, and during surgery, to optimally position the implant in the patient. Ortoma's surgical system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries – and thus better long-term survival rates for implants. OTS is a system that is easily integrated into the processes and routines currently used in surgery, thereby increasing efficiency. Globally, more than 7.5 million orthopedic procedures are performed each year where OTS could be used in hip, knee and spinal surgery. Ortoma's B shares are listed on Nasdaq First North Growth Market Stockholm. Redeye Nordic Growth AB is Certified Adviser for Ortoma. For more information see: www.ortoma.com

Attachments

[The subscription period in Ortoma's rights issue begins today](#)